$1.16 Billion in Sales Expected for Diplomat Pharmacy, Inc. (DPLO) This Quarter
Wall Street brokerages expect that Diplomat Pharmacy, Inc. (NYSE:DPLO) will announce sales of $1.16 billion for the current quarter, according to Zacks. Six analysts have provided estimates for Diplomat Pharmacy’s earnings. The highest sales estimate is $1.18 billion and the lowest is $1.14 billion. Diplomat Pharmacy reported sales of $1.14 billion in the same quarter last year, which would suggest a positive year-over-year growth rate of 1.8%. The company is scheduled to issue its next quarterly earnings results on Tuesday, February 27th.
According to Zacks, analysts expect that Diplomat Pharmacy will report full-year sales of $1.16 billion for the current fiscal year, with estimates ranging from $4.46 billion to $4.51 billion. For the next year, analysts expect that the company will report sales of $5.10 billion per share, with estimates ranging from $4.89 billion to $5.28 billion. Zacks’ sales averages are an average based on a survey of analysts that that provide coverage for Diplomat Pharmacy.
Diplomat Pharmacy (NYSE:DPLO) last posted its quarterly earnings results on Monday, November 6th. The company reported $0.25 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.15 by $0.10. Diplomat Pharmacy had a return on equity of 8.30% and a net margin of 0.18%. The business had revenue of $1.12 billion during the quarter, compared to the consensus estimate of $1.16 billion. During the same period in the prior year, the company posted $0.21 EPS. The firm’s revenue for the quarter was down 4.8% compared to the same quarter last year.
Several analysts have recently issued reports on DPLO shares. Robert W. Baird raised Diplomat Pharmacy to a “positive” rating and upped their price objective for the stock from $20.00 to $24.00 in a report on Monday, September 18th. Zacks Investment Research cut Diplomat Pharmacy from a “hold” rating to a “sell” rating in a report on Monday, July 17th. Needham & Company LLC started coverage on Diplomat Pharmacy in a report on Friday, July 21st. They set a “buy” rating and a $19.75 price objective on the stock. BidaskClub raised Diplomat Pharmacy from a “buy” rating to a “strong-buy” rating in a report on Thursday, October 5th. Finally, Mizuho set a $16.00 price objective on Diplomat Pharmacy and gave the stock a “hold” rating in a report on Tuesday, October 24th. One research analyst has rated the stock with a sell rating, five have given a hold rating, three have assigned a buy rating and one has given a strong buy rating to the stock. Diplomat Pharmacy currently has an average rating of “Hold” and an average price target of $20.06.
Diplomat Pharmacy (NYSE DPLO) traded down $0.53 during mid-day trading on Wednesday, reaching $19.66. The company’s stock had a trading volume of 333,700 shares, compared to its average volume of 785,191. Diplomat Pharmacy has a 1-year low of $12.25 and a 1-year high of $21.99. The company has a quick ratio of 0.88, a current ratio of 1.34 and a debt-to-equity ratio of 0.18. The company has a market cap of $1,320.00, a P/E ratio of 26.22, a price-to-earnings-growth ratio of 3.63 and a beta of 0.74.
COPYRIGHT VIOLATION WARNING: This story was first published by Watch List News and is the sole property of of Watch List News. If you are viewing this story on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://www.watchlistnews.com/1-16-billion-in-sales-expected-for-diplomat-pharmacy-inc-dplo-this-quarter/1696768.html.
A number of large investors have recently added to or reduced their stakes in DPLO. Parametric Portfolio Associates LLC raised its holdings in Diplomat Pharmacy by 114.3% during the 1st quarter. Parametric Portfolio Associates LLC now owns 55,899 shares of the company’s stock valued at $892,000 after buying an additional 29,819 shares during the period. JPMorgan Chase & Co. raised its holdings in Diplomat Pharmacy by 73.1% during the 1st quarter. JPMorgan Chase & Co. now owns 7,235 shares of the company’s stock valued at $116,000 after buying an additional 3,056 shares during the period. Prudential Financial Inc. raised its holdings in Diplomat Pharmacy by 4.0% during the 1st quarter. Prudential Financial Inc. now owns 74,470 shares of the company’s stock valued at $1,188,000 after buying an additional 2,840 shares during the period. Principal Financial Group Inc. raised its holdings in Diplomat Pharmacy by 5.0% during the 1st quarter. Principal Financial Group Inc. now owns 329,853 shares of the company’s stock valued at $5,261,000 after buying an additional 15,576 shares during the period. Finally, Teachers Advisors LLC raised its holdings in Diplomat Pharmacy by 112.8% during the 1st quarter. Teachers Advisors LLC now owns 279,303 shares of the company’s stock valued at $4,455,000 after buying an additional 148,060 shares during the period. Institutional investors own 67.36% of the company’s stock.
Diplomat Pharmacy Company Profile
Diplomat Pharmacy, Inc (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Diplomat Pharmacy Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.